PD‐L1 and CD47 co‐expression predicts survival and enlightens future dual‐targeting immunotherapy in non‐small cell lung cancer

Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non‐small cell lung cancer

(2020) Oscar Arrieta et al.   Cancer Medicine

Trispecific antibodies take to the clinic

(2020) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades

(2019) Tao Lu et al.   Cancer Management and Research

Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)

(2019) Ping-Chih Hsu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy

(2019) Zhenlin Yang et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

CD47: role in the immune system and application to cancer therapy

(2019) Seyed Mohammad Gheibi Hayat et al.   CELLULAR ONCOLOGY

The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients

(2019) Bing-Yen Wang et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Bispecific antibody based therapeutics: Strengths and challenges

(2018) Archana Thakur et al.   BLOOD REVIEWS

PD-1/PD-L1 Axis in Lung Cancer

(2018) Fernando C. Santini et al.   CANCER JOURNAL

CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises

(2018) Bing Tong et al.   Future Oncology

PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements

(2018) Yasuto Yoneshima et al.   LUNG CANCER

Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma

(2017) Chun-yu Huang et al.   JOURNAL OF IMMUNOTHERAPY

Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy

(2017) Thomas J Gniadek et al.   MODERN PATHOLOGY

Significance of CD47 expression in gastric cancer

(2017) Tomoya Sudo et al.   Oncology Letters

Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer

(2017) Gen Lin et al.   Oncotarget

Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration

(2016) C.-Y. Ock et al.   CLINICAL CANCER RESEARCH

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

(2016) Junzo Hamanishi et al.   International Journal of Clinical Oncology

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer

(2016) Kipp Weiskopf et al.   JOURNAL OF CLINICAL INVESTIGATION

PD-L1 Expression in Lung Cancer

(2016) Hui Yu et al.   Journal of Thoracic Oncology

Durable antitumor responses to CD47 blockade require adaptive immune stimulation

(2016) Jonathan T. Sockolosky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer

(2016) Sukhbir Kaur et al.   Oncotarget

CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer

(2016) Hui Zhao et al.   Scientific Reports

Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma

(2015) Zhenyu Xiao et al.   CANCER LETTERS

Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy

(2015) Keishi Adachi et al.   CANCER SCIENCE

CD47 protein expression in acute myeloid leukemia: A tissue microarray-based analysis

(2015) Serena Galli et al.   LEUKEMIA RESEARCH

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma

(2015) Wendy A. Cooper et al.   LUNG CANCER

CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer

(2015) Kazumichi Yoshida et al.   Cancer Medicine

Heterogeneity in the Differentiation and Function of CD8+ T Cells

(2014) Hans-Willi Mittrücker et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

CD47 and Osteopontin Expression in Diffuse Large B-cell Lymphoma With Nodal and Intravascular Involvement

(2013) Jason S. Starr et al.   Clinical Lymphoma Myeloma & Leukemia

Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response

(2013) D. Tseng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

(2009) Siddhartha Jaiswal et al.   CELL